TScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies

Tscan Therapeutics, Inc. ((TCRX)) announced an update on their ongoing clinical study.

Study Overview: TScan Therapeutics, Inc. is conducting a long-term follow-up study titled A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product. The study aims to monitor the long-term safety and efficacy of TSC-100 and TSC-101 TCR-T therapies in participants who previously received treatment in the TSCAN-001 study. This research is significant as it seeks to provide insights into the prolonged effects and safety of these innovative therapies for conditions like AML, ALL, and MDS.

Intervention/Treatment: The study focuses on an observational approach, with no new drugs administered. It evaluates participants previously treated with TSC-100 or TSC-101 TCR-T products to assess their long-term safety and efficacy.

Study Design: This is an observational study with a prospective time perspective. It involves collecting approximately 20 ml of whole blood at each visit to monitor participants over a 15-year period, ensuring a comprehensive assessment of the long-term impact of the TCR-T therapies.

Study Timeline: The study began on April 18, 2025, with the latest update submitted on September 2, 2025. These dates are crucial as they mark the commencement and recent progress of the study, indicating ongoing recruitment and data collection.

Market Implications: The update on this long-term follow-up study could positively influence TScan Therapeutics’ stock performance by reinforcing investor confidence in the safety and efficacy of its TCR-T products. As the biotech industry increasingly focuses on innovative cancer therapies, successful long-term results could position TScan favorably against competitors, potentially driving investor interest and market value.

The study is ongoing, with further details available on the ClinicalTrials portal.